Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Liabilities from Discontinued Operations: 2023

Historic Liabilities from Discontinued Operations for Cidara Therapeutics (CDTX) over the last 1 years, with Dec 2023 value amounting to $24.7 million.

  • Cidara Therapeutics' Liabilities from Discontinued Operations was N/A to $11,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $11,000, marking a year-over-year change of. This contributed to the annual value of $24.7 million for FY2023, which is N/A change from last year.
  • As of FY2023, Cidara Therapeutics' Liabilities from Discontinued Operations stood at $24.7 million.
  • Cidara Therapeutics' 5-year Liabilities from Discontinued Operations high stood at $24.7 million for FY2023, and its period low was $24.7 million during FY2023.
  • Its 1-year average for Liabilities from Discontinued Operations is $24.7 million, with a median of $24.7 million in 2023.